Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab in Primary Autoimmune Blood Cell Disorders
NCT07104565Phase 2Recruiting
- Sponsor
- Incyte
- Start
- Dec 2025
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of tafasitamab in immune thrombocytopenia (ITP), warm autoimmune hemolytic anemia (wAIHA), sponsored by Incyte. Started Dec 2025; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT07104565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07104565.